BioNxt Solutions Past Earnings Performance
Past criteria checks 0/6
BioNxt Solutions has been growing earnings at an average annual rate of 6.6%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been declining at an average rate of 3% per year.
Key information
6.6%
Earnings growth rate
20.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -3.0% |
| Return on equity | n/a |
| Net Margin | -15,422.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How BioNxt Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -6 | 3 | 2 |
| 30 Jun 24 | 0 | -6 | 3 | 2 |
| 31 Mar 24 | 0 | -8 | 4 | 2 |
| 31 Dec 23 | 0 | -8 | 4 | 3 |
| 30 Sep 23 | 0 | -13 | 4 | 2 |
| 30 Jun 23 | 0 | -13 | 4 | 2 |
| 31 Mar 23 | 0 | -12 | 4 | 2 |
| 31 Dec 22 | 0 | -12 | 4 | 2 |
| 30 Sep 22 | 0 | -14 | 6 | 2 |
| 30 Jun 22 | 0 | -14 | 8 | 2 |
| 31 Mar 22 | 0 | -17 | 9 | 3 |
| 31 Dec 21 | 0 | -21 | 12 | 3 |
| 30 Sep 21 | 0 | -15 | 10 | 3 |
| 30 Jun 21 | 0 | -19 | 12 | 4 |
| 31 Mar 21 | 0 | -19 | 11 | 4 |
| 31 Dec 20 | 0 | -17 | 11 | 3 |
| 30 Sep 20 | 0 | -16 | 10 | 3 |
| 30 Jun 20 | 0 | -13 | 10 | 2 |
| 31 Mar 20 | 0 | -10 | 9 | 1 |
| 31 Dec 19 | 0 | -8 | 6 | 1 |
| 30 Sep 19 | 0 | -6 | 5 | 0 |
| 30 Jun 19 | 0 | -2 | 2 | 0 |
| 31 Mar 19 | 0 | -2 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 1 | 0 |
Quality Earnings: BNXT is currently unprofitable.
Growing Profit Margin: BNXT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNXT is unprofitable, but has reduced losses over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare BNXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-52.2%).
Return on Equity
High ROE: BNXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.